• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » FDA approves St. Jude Medical’s Infinity DBS and directional leads

FDA approves St. Jude Medical’s Infinity DBS and directional leads

October 6, 2016 By Brad Perriello

St. Jude Medical's Infinity DBSSt. Jude Medical (NYSE:STJ) said today that the FDA approved its Infinity deep-brain stimulation device, including its DBS directional leads, to treat Parkinson’s disease and essential tremor.

The Infinity system is designed so that Apple (NSDQ:AAPL) mobile devices can be used as wireless controllers, via a Bluetooth connection; St. Jude claims the system as the only upgradable DBS platform for movement disorders.

The directional leads, the 1st to a nod from the U.S. safety watchdog, are designed to allow doctors to “steer” current to different parts of the brain, tailoring treatment to reduce side effects. Patients using the Infinity system can link it to Apple’s iPod Touch; physicians can program the device using the Apple iPad Mini, according to the company.

The 1st Infinity implantation in the U.S. was performed by Dr. Kelly Foote of the University of Florida Center for Movement Disorders & Neurorestoration at the UF Health Shands Hospital, St. Jude said.

“I’m very happy that the Infinity DBS system and its directional DBS lead are now available in the U.S. I believe that the directional lead represents an important advancement in DBS technology that has the potential to improve outcomes of DBS therapy for many patients. This new system offers the potential to diminish adverse effects of DBS by steering current away from areas of the brain that cause side effects, allowing us to better control the symptoms of Parkinson’s disease and essential tremor,” Foote said in prepared remarks.

“The St. Jude Medical Infinity DBS system and directional lead represent St. Jude Medical’s commitment to the treatment of debilitating movement disorders,” added St. Jude neuromodulation medical director Dr. Allen Burton. “The new St. Jude Medical Infinity system was designed to streamline therapy programming, allowing physicians more time to provide care to more patients. The system was also designed to provide patients with the best possible experience to manage their symptoms in a discreet manner that fits more easily into their lives.”

In June, St. Jude announced the European launch of the Infinity system and directional lead, after winning CE Mark approval in the European Union in September 2015.

Filed Under: Food & Drug Administration (FDA), Neuromodulation/Neurostimulation, Regulatory/Compliance Tagged With: stjudemedical

More recent news

  • Zimmer Biomet, Think Surgical extend exclusive distribution agreement
  • Cambridge Heartwear inks £184M deal to supply NHS with portable ECG monitors
  • J&J, Smith+Nephew plans for ortho megamerger reportedly fall through
  • California and Massachusetts still reign as top US medtech headquarters locations
  • Teleflex wins Breakthrough Device designation for Freesolve resorbable scaffold

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy